secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001493152-23-044598
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics enters $25M equity line with Yorkville; director resignation and replacement
--------------------------------------------------------------------------------

- SEPA provides up to $25M (expandable to $50M) of common stock at 97% of market price over 36 months.
- Commitment fee of $250,000 in shares and $25,000 structuring fee; advance capped at 5M shares or 100% of 5-day avg volume.
- Director Thomas Vecchiolla resigns effective Jan 1, 2024; David LaPre appointed to fill vacancy as independent director.
- Issuance capped at 19.99% of outstanding shares unless shareholder approval or price test met; requires effective registration statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/0001493152-23-044598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-044598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer